Eli Lilly (NYSE: LLY) is part of this group. On Sept. 16, the drugmaker announced plans to build a $5 billion facility in ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

"Eli Lilly buys Adverum in eye disease gene therapy punt" was originally created and published by Pharmaceutical Technology, ...

Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in ...

Eli Lilly and Johnson & Johnson are joining fellow Big Pharma peers in upping their investment in AI, with Lilly looking to ...

Eli Lilly & Company (NYSE:LLY) ranks among the best fundamental stocks to buy right now. Eli Lilly & Company (NYSE:LLY) revealed plans on September 16 to build a $5 billion manufacturing facility in ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...

Oct 14 (Reuters) - Eli Lilly & Co (LLY.N), opens new tab on Wednesday said other trials of its experimental coronavirus antibody therapy remain on track after a government-run study testing the ...

Eli Lilly is building a $5 billion manufacturing facility in Richmond, Va. It is the company’s first fully integrated facility for active pharmaceutical ingredients. The site is also intended to ...

Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of its ...

Oct 7 (Reuters) - Eli Lilly and Co (LLY.N), opens new tab on Wednesday said it applied for U.S. emergency use authorization (EUA) for its experimental COVID-19 antibody treatment and plans to pursue a ...